

ASX ANNOUNCEMENT

RESULTS OF GENERAL MEETING

Sydney Australia, 10 April 2014

Benitec Biopharma Limited (ASX: BLT) is pleased to announce the successful outcome from today's General Meeting. Support from shareholders to approve the resolutions was overwhelmingly positive, with the results detailed below.

The effect of this vote is that the Company will receive \$29.5 million in new funding from ten US and international institutional investors in addition to \$2.0 million from existing institutional and professional investors in Australia.

Benitec CEO, Dr Peter French commented on the meeting outcome: "The Benitec Board is very pleased by the level of response from shareholders who lodged proxy votes. Over 30% of eligible shares were voted, which is the highest response rate we have had in such votes. We appreciate the extremely high level of support shown by shareholders for the resolutions. This institutional capital raise has been a transformational event for the company, and will allow us to advance our broad pipeline of ddRNAi-based therapeutics towards multiple clinically staged assets."

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, the resolutions and the proxies received in respect of each resolution at this morning's General Meeting were:

Resolution 1, Ratification of Prior Issue of Shares and Options

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Open Usable	Against	Abstain
28,222,561	1,073,507	868,192	146,471

The motion was carried as an ordinary resolution on a show of hands.

Resolution 2, Approval to Issue Shares and Options

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Open Usable	Against	Abstain
27,763,184	1,071,998	1,350,252	125,297

The motion was carried as an ordinary resolution on a show of hands.

For further information, please contact the persons below, or visit the Benitec website at www.benitec.com.



Company	Investor relations
Carl Stubbings Chief Business Officer Tel: +61 (2) 9555 6986 Email: cstubbings@benitec.com	Jane Lowe Buchan Consulting Tel: +61 (2) 9237 2807 Email: jlowe@buchanwe.com.au

About Benitec Biopharma Limited:

Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX Code: BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as Hepatitis C, Hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington's disease. For more information on Benitec refer to the Company's website at www.benitec.com.